1
|
Toledo-Stuardo K, Ribeiro CH, Campos I, Tello S, Latorre Y, Altamirano C, Dubois-Camacho K, Molina MC. Impact of MICA 3'UTR allelic variability on miRNA binding prediction, a bioinformatic approach. Front Genet 2023; 14:1273296. [PMID: 38146340 PMCID: PMC10749337 DOI: 10.3389/fgene.2023.1273296] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2023] [Accepted: 11/13/2023] [Indexed: 12/27/2023] Open
Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that participate as powerful genetic regulators. MiRNAs can interfere with cellular processes by interacting with a broad spectrum of target genes under physiological and pathological states, including cancer development and progression. Major histocompatibility complex major histocompatibility complex class I-related chain A (MICA) belongs to a family of proteins that bind the natural-killer group 2, member D (NKG2D) receptor on Natural Killer cells and other cytotoxic lymphocytes. MICA plays a crucial role in the host's innate immune response to several disease settings, including cancer. MICA harbors various single nucleotide polymorphisms (SNPs) located in its 3'-untranslated region (3'UTR), a characteristic that increases the complexity of MICA regulation, favoring its post-transcriptional modulation by miRNAs under physiological and pathological conditions. Here, we conducted an in-depth analysis of MICA 3'UTR sequences according to each MICA allele described to date using NCBI database. We also systematically evaluated interactions between miRNAs and their putative targets on MICA 3'UTR containing SNPs using in silico analysis. Our in silico results showed that MICA SNPs rs9266829, rs 1880, and rs9266825, located in the target sequence of miRNAs hsa-miR-106a-5p, hsa-miR-17-5p, hsa-miR-20a-5p, hsa-miR-20b-5p, hsa-miR-93, hsa-miR-1207.5p, and hsa-miR-711 could modify the binding free energy between -8.62 and -18.14 kcal/mol, which may affect the regulation of MICA expression. We believe that our results may provide a starting point for further exploration of miRNA regulatory effects depending on MICA allelic variability; they may also be a guide to conduct miRNA in silico analysis for other highly polymorphic genes.
Collapse
Affiliation(s)
- Karen Toledo-Stuardo
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
| | - Carolina H. Ribeiro
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
| | - Ivo Campos
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
| | - Samantha Tello
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
| | - Yesenia Latorre
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
- School of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile
| | - Claudia Altamirano
- School of Biochemical Engineering, Pontificia Universidad Católica de Valparaíso, Valparaíso, Chile
| | - Karen Dubois-Camacho
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
- Faculty of Medicine, Clinical and Molecular Pharmacology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
- Gastroenterology and Hepatology Department, University Medical Center Groningen, Groningen, Netherlands
| | - Maria Carmen Molina
- Faculty of Medicine, Immunology Program, Institute of Biomedical Sciences (ICBM), Universidad de Chile, Santiago, Chile
| |
Collapse
|
2
|
Koskela S, Tammi S, Clancy J, Lucas JAM, Turner TR, Hyvärinen K, Ritari J, Partanen J. MICA and MICB allele assortment in Finland. HLA 2023. [PMID: 36919857 DOI: 10.1111/tan.15023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 02/01/2023] [Accepted: 03/04/2023] [Indexed: 03/16/2023]
Abstract
Genetic variation in the MICA and MICB genes located within the major histocompatibility complex region has been reported to be associated with transplantation outcome and susceptibility to autoimmune diseases and infections. Only limited data of polymorphism in these genes in different populations are available. We here report allelic variation at 2-field resolution and the haplotypes of the MICA and MICB genes in Finland (n = 1032 individuals), a north European population with historical bottleneck and founder effects. Altogether 24 MICA and 18 MICB alleles were found, forming 70 estimated MICA-MICB haplotypes. As compared to other populations frequency differences were found, for example, MICA*010:01 was found to be at an allele frequency of 0.133 in Finland which is higher than in other European populations (0.021-0.077), but close to Asian populations (0.151-0.220). Three novel alleles with amino acid change are described. The results demonstrate a relatively high level of polymorphism and population differences in MICA and MICB allele distribution.
Collapse
Affiliation(s)
- Satu Koskela
- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland.,Finnish Red Cross Blood Service Biobank, Helsinki, Finland
| | - Silja Tammi
- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland.,Finnish Red Cross Blood Service Biobank, Helsinki, Finland
| | - Jonna Clancy
- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland.,Finnish Red Cross Blood Service Biobank, Helsinki, Finland
| | | | - Thomas R Turner
- Anthony Nolan Research Institute, Royal Free Hospital, London, UK.,UCL Cancer Institute, Royal Free Campus, London, UK
| | - Kati Hyvärinen
- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland
| | - Jarmo Ritari
- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland
| | - Jukka Partanen
- Finnish Red Cross Blood Service, Research and Development, Helsinki, Finland.,Finnish Red Cross Blood Service Biobank, Helsinki, Finland
| |
Collapse
|
3
|
Lindsø Andersen P, Jemec GB, Erikstrup C, Didriksen M, Dinh KM, Mikkelsen S, Sørensen E, Nielsen KR, Bruun MT, Hjalgrim H, Hansen TF, Sækmose SG, Ostrowski SR, Saunte DML, Pedersen OB. Human leukocyte antigen system associations in Malassezia-related skin diseases. Arch Dermatol Res 2022; 315:895-902. [PMID: 36394635 DOI: 10.1007/s00403-022-02454-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 10/10/2022] [Accepted: 10/31/2022] [Indexed: 11/18/2022]
Abstract
BACKGROUND The human leukocyte antigen system (HLA) is divided into two classes involved in antigen presentation: class I presenting intracellular antigens and class II presenting extracellular antigens. While susceptibility to infections is correlated with the HLA system, data on associations between HLA genotypes and Malassezia-related skin diseases (MRSD) are lacking. Thus, the objective of this study was to investigate associations between HLA alleles and MRSD. MATERIALS AND METHODS Participants in The Danish Blood Donor Study (2010-2018) provided questionnaire data on life style, anthropometric measures, and registry data on filled prescriptions. Genotyping was done using Illumina Infinium Global Screening Array, and HLA alleles were imputed using the HIBAG algorithm. Cases and controls were defined using filled prescriptions on topical ketoconazole 2% as a proxy of MRSD. Logistic regressions assessed associations between HLA alleles and MRSD adjusted for confounders and Bonferroni corrected for multiple tests. RESULTS A total of 9455 participants were considered MRSD cases and 24,144 participants as controls. We identified four risk alleles B*57:01, OR 1.19 (95% CI: 1.09-1.31), C*01:02, OR 1.19 (95% CI: 1.08-1.32), C*06:02, OR 1.14 (95% CI: 1.08-1.22), and DRB1*01:01, OR 1.10 (95% CI: 1.04-1.17), and two protective alleles, DQB1*02:01, OR 0.89 (95% CI: 0.85-0.94), and DRB1*03:01, OR 0.89 (95% CI: 0.85-0.94). CONCLUSION Five novel associations between HLA alleles and MRSD were identified in our cohort, and one previous association was confirmed. Future studies should assess the correlation between Malassezia antigens and antigen-binding properties of the associated HLA alleles.
Collapse
Affiliation(s)
- P Lindsø Andersen
- Department of Dermatology, Zealand University Hospital Roskilde, Sygehusvej 5, 4000, Roskilde, Denmark.
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark.
| | - G B Jemec
- Department of Dermatology, Zealand University Hospital Roskilde, Sygehusvej 5, 4000, Roskilde, Denmark
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
| | - C Erikstrup
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
| | - M Didriksen
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - K M Dinh
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
- Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark
| | - S Mikkelsen
- Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark
| | - E Sørensen
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - K R Nielsen
- Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark
| | - M T Bruun
- Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
| | - H Hjalgrim
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
- Department of Epidemiology Research, Statens Serum Institute, Copenhagen, Denmark
- Danish Cancer Society Research Center, Copenhagen, Denmark
- Department of Haematology, Rigshospitalet, Copenhagen, Denmark
| | - T F Hansen
- Department of Neurology, Danish Headache Center, Copenhagen University Hospital, Glostrup, Denmark
- The Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - S G Sækmose
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
| | - S R Ostrowski
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
- Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - D M L Saunte
- Department of Dermatology, Zealand University Hospital Roskilde, Sygehusvej 5, 4000, Roskilde, Denmark
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
| | - O B Pedersen
- Department of Clinical Immunology, Zealand University Hospital, Køge, Denmark
- Department of Clinical Medicine, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
4
|
Al Hadra B, Lukanov TI, Ivanova MI. HLA class I chain-related MICA and MICB genes polymorphism in healthy individuals from the Bulgarian population. Hum Immunol 2022; 83:551-555. [PMID: 35525711 DOI: 10.1016/j.humimm.2022.04.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2022] [Revised: 04/01/2022] [Accepted: 04/18/2022] [Indexed: 11/26/2022]
Abstract
Although human leukocyte antigen (HLA) gene polymorphism has been investigated in many populations around the world, the data on MHC class I chain-related (MIC) genes are still limited. The present study is aimed to analyze the allelic polymorphism of MICA and MICB genes and haplotype associations with HLA-B locus in 132 healthy, unrelated individuals from the Bulgarian population by next generation sequencing (NGS). A total of 36 MICA and 16 MICB alleles were observed with the highest frequency detected for MICA*008:01 (17.1%) and MICB*005:02 (32.4%). Further, two and three-loci haplotype frequencies and pairwise linkage disequilibrium were estimated. Highly significant global linkage disequilibrium was found between either HLA-B and MICA and MICB genes. This is the first study on MICA and MICB allelic polymorphism, linkage disequilibrium, and haplotype polymorphism in the Bulgarian population. These results will allow for better characterization of the genetic heterogeneity of the Bulgarian population and could contribute to further analyses on MICA and MICB clinical significance.
Collapse
Affiliation(s)
- Bushra Al Hadra
- Department of Clinical Immunology, Medical University, Sofia, Bulgaria; Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Sofia, Bulgaria.
| | - Tsvetelin I Lukanov
- Department of Clinical Immunology, Medical University, Sofia, Bulgaria; Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Sofia, Bulgaria
| | - Milena I Ivanova
- Department of Clinical Immunology, Medical University, Sofia, Bulgaria; Department of Clinical Immunology and Stem Cell Bank, Alexandrovska University Hospital, Sofia, Bulgaria
| |
Collapse
|
5
|
Toledo-Stuardo K, Ribeiro CH, Canals A, Morales M, Gárate V, Rodríguez-Siza J, Tello S, Bustamante M, Armisen R, Matthies DJ, Zapata-Torres G, González-Hormazabal P, Molina MC. Major Histocompatibility Complex Class I-Related Chain A (MICA) Allelic Variants Associate With Susceptibility and Prognosis of Gastric Cancer. Front Immunol 2021; 12:645528. [PMID: 33868281 PMCID: PMC8045969 DOI: 10.3389/fimmu.2021.645528] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Accepted: 02/23/2021] [Indexed: 12/14/2022] Open
Abstract
Gastric cancer (GC) is the fifth most prevalent type of cancer worldwide. Gastric tumor cells express MICA protein, a ligand to NKG2D receptor that triggers natural killer (NK) cells effector functions for early tumor elimination. MICA gene is highly polymorphic, thus originating alleles that encode protein variants with a controversial role in cancer. The main goal of this work was to study MICA gene polymorphisms and their relationship with the susceptibility and prognosis of GC. Fifty patients with GC and 50 healthy volunteers were included in this study. MICA alleles were identified using Sanger sequencing methods. The analysis of MICA gene sequence revealed 13 MICA sequences and 5 MICA-short tandem repeats (STR) alleles in the studied cohorts We identified MICA*002 (*A9) as the most frequent allele in both, patients and controls, followed by MICA*008 allele (*A5.1). MICA*009/049 allele was significantly associated with increased risk of GC (OR: 5.11 [95% CI: 1.39–18.74], p = 0.014). The analysis of MICA-STR alleles revealed a higher frequency of MICA*A5 in healthy individuals than GC patients (OR = 0.34 [95% CI: 0.12–0.98], p = 0.046). Survival analysis after gastrectomy showed that patients with MICA*002/002 or MICA*002/004 alleles had significantly higher survival rates than those patients bearing MICA*002/008 (p = 0.014) or MICA*002/009 (MICA*002/049) alleles (p = 0.040). The presence of threonine in the position MICA-181 (MICA*009/049 allele) was more frequent in GC patients than controls (p = 0.023). Molecular analysis of MICA-181 showed that the presence of threonine provides greater mobility to the protein than arginine in the same position (MICA*004), which could explain, at least in part, some immune evasion mechanisms developed by the tumor. In conclusion, our findings suggest that the study of MICA alleles is crucial to search for new therapeutic approaches and may be useful for the evaluation of risk and prognosis of GC and personalized therapy.
Collapse
Affiliation(s)
- Karen Toledo-Stuardo
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Carolina H Ribeiro
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Andrea Canals
- Biostatistics Program, School of Public Health, University of Chile, Santiago, Chile.,Academic Direction, Clínica Santa María, Santiago, Chile
| | - Marcela Morales
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Valentina Gárate
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Jose Rodríguez-Siza
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Samantha Tello
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| | - Marco Bustamante
- Department of Surgery (Oriente), Hospital del Salvador, University of Chile, Santiago, Chile
| | - Ricardo Armisen
- Center of Genetics and Genomics, Faculty of Medicine Clínica Alemana, Institute for Sciences and Innovations in Medicine (ICIM), Universidad del Desarrollo, Santiago, Chile
| | - Douglas J Matthies
- Department of Inorganic and Analytical Chemistry, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Santiago, Chile
| | - Gerald Zapata-Torres
- Department of Inorganic and Analytical Chemistry, Faculty of Chemical and Pharmaceutical Sciences, University of Chile, Santiago, Chile
| | | | - María Carmen Molina
- Immunology Program, Faculty of Medicine, Institute of Biomedical Sciences (ICBM), University of Chile, Santiago, Chile
| |
Collapse
|
6
|
Carapito R, Aouadi I, Pichot A, Spinnhirny P, Morlon A, Kotova I, Macquin C, Rolli V, Cesbron A, Gagne K, Oudshoorn M, van der Holt B, Labalette M, Spierings E, Picard C, Loiseau P, Tamouza R, Toubert A, Parissiadis A, Dubois V, Paillard C, Maumy-Bertrand M, Bertrand F, von dem Borne PA, Kuball JHE, Michallet M, Lioure B, Peffault de Latour R, Blaise D, Cornelissen JJ, Yakoub-Agha I, Claas F, Moreau P, Charron D, Mohty M, Morishima Y, Socié G, Bahram S. Compatibility at amino acid position 98 of MICB reduces the incidence of graft-versus-host disease in conjunction with the CMV status. Bone Marrow Transplant 2020; 55:1367-1378. [PMID: 32286503 DOI: 10.1038/s41409-020-0886-5] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 03/17/2020] [Accepted: 03/23/2020] [Indexed: 11/10/2022]
Abstract
Graft-versus-host disease (GVHD) and cytomegalovirus (CMV)-related complications are leading causes of mortality after unrelated-donor hematopoietic cell transplantation (UD-HCT). The non-conventional MHC class I gene MICB, alike MICA, encodes a stress-induced polymorphic NKG2D ligand. However, unlike MICA, MICB interacts with the CMV-encoded UL16, which sequestrates MICB intracellularly, leading to immune evasion. Here, we retrospectively analyzed the impact of mismatches in MICB amino acid position 98 (MICB98), a key polymorphic residue involved in UL16 binding, in 943 UD-HCT pairs who were allele-matched at HLA-A, -B, -C, -DRB1, -DQB1 and MICA loci. HLA-DP typing was further available. MICB98 mismatches were significantly associated with an increased incidence of acute (grade II-IV: HR, 1.20; 95% CI, 1.15 to 1.24; P < 0.001; grade III-IV: HR, 2.28; 95% CI, 1.56 to 3.34; P < 0.001) and chronic GVHD (HR, 1.21; 95% CI, 1.10 to 1.33; P < 0.001). MICB98 matching significantly reduced the effect of CMV status on overall mortality from a hazard ratio of 1.77 to 1.16. MICB98 mismatches showed a GVHD-independent association with a higher incidence of CMV infection/reactivation (HR, 1.84; 95% CI, 1.34 to 2.51; P < 0.001). Hence selecting a MICB98-matched donor significantly reduces the GVHD incidence and lowers the impact of CMV status on overall survival.
Collapse
Affiliation(s)
- Raphael Carapito
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France. .,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France. .,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France. .,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan. .,Laboratoire d'Immunologie, Plateau Technique de Biologie, Pôle de Biologie, Nouvel Hôpital Civil, Strasbourg, France.
| | - Ismail Aouadi
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan
| | - Angélique Pichot
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan
| | - Perrine Spinnhirny
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan
| | - Aurore Morlon
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,BIOMICA SAS, Strasbourg, France
| | - Irina Kotova
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,BIOMICA SAS, Strasbourg, France
| | - Cécile Macquin
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan
| | - Véronique Rolli
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France.,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan
| | - Anne Cesbron
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Etablissement Français du Sang (EFS) Centre-Pays de la Loire, Laboratoire HLA, Nantes, France.,Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Société Francophone d'Histocompatibilité et d'Immunogénétique (SFHI), Paris, France
| | - Katia Gagne
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Etablissement Français du Sang (EFS) Centre-Pays de la Loire, Laboratoire HLA, Nantes, France.,INSERM 1232, CRCINA, Université Nantes-Angers, Nantes, France
| | - Machteld Oudshoorn
- Europdonor operated by Matchis Foundation, Leiden, The Netherlands.,Department of Immunohematology and Blood transfusion, LUMC, Leiden, The Netherlands
| | - Bronno van der Holt
- HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Myriam Labalette
- Laboratoire d'Immunologie, CHRU de Lille, Lille, France.,LIRIC INSERM U995, Université Lille 2, Lille, France
| | - Eric Spierings
- Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Christophe Picard
- CNRS, EFS-PACA, ADES UMR 7268, Aix-Marseille Université, Marseille, France
| | - Pascale Loiseau
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Laboratoire Jean Dausset, INSERM UMR_S 1160, Hôpital Saint-Louis, Paris, France
| | - Ryad Tamouza
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Laboratoire Jean Dausset, INSERM UMR_S 1160, Hôpital Saint-Louis, Paris, France
| | - Antoine Toubert
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Laboratoire Jean Dausset, INSERM UMR_S 1160, Hôpital Saint-Louis, Paris, France
| | - Anne Parissiadis
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Etablissement Français du Sang (EFS) Grand-Est, Laboratoire HLA, Strasbourg, France
| | - Valérie Dubois
- Etablissement Français du Sang (EFS) Rhône-Alpes, Laboratoire HLA, Lyon, France
| | - Catherine Paillard
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Service d'Hématologie et d'Oncologie pédiatrique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Myriam Maumy-Bertrand
- Institut de Recherche Mathématique Avancée, CNRS UMR 7501, LabEx Institut de Recherche en Mathématiques, ses Interactions et Applications, Université de Strasbourg, Strasbourg, France
| | - Frédéric Bertrand
- Institut de Recherche Mathématique Avancée, CNRS UMR 7501, LabEx Institut de Recherche en Mathématiques, ses Interactions et Applications, Université de Strasbourg, Strasbourg, France
| | | | - Jürgen H E Kuball
- Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Mauricette Michallet
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Centre Hospitalier Lyon Sud, Hématologie 1G, Hospices Civils de Lyon, Pierre Bénite, Lyon, France
| | - Bruno Lioure
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Service d'Hématologie Adulte, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Régis Peffault de Latour
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Service d'Hématologie - Greffe, Hôpital Saint-Louis, APHP, Paris, France
| | - Didier Blaise
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Institut Paoli Calmettes, Marseille, France
| | - Jan J Cornelissen
- Department of Hematology and ErasmusMC Cancer Institute, Erasmus University Medical Center, Rotterdam, The Netherlands
| | - Ibrahim Yakoub-Agha
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,LIRIC INSERM U995, Université Lille 2, Lille, France
| | - Frans Claas
- Department of Immunohematology and Blood transfusion, LUMC, Leiden, The Netherlands
| | - Philippe Moreau
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Service d'Hématologie Clinique, CHU Hôtel Dieu, Nantes, France
| | - Dominique Charron
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Laboratoire Jean Dausset, INSERM UMR_S 1160, Hôpital Saint-Louis, Paris, France
| | - Mohamad Mohty
- Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Département d'Hématologie, Hôpital Saint Antoine, Paris, France.,Université Pierre & Marie Curie, Paris, France.,Centre de Recherche Saint-Antoine, INSERM UMR_S 938, Paris, France
| | - Yasuo Morishima
- Division of Epidemiology and Prevention, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa-ku, Nagoya, Japan
| | - Gérard Socié
- Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France.,Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Hôpital Edouard Herriot, CHU, Lyon, France.,Service d'Hématologie Adulte, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - Seiamak Bahram
- Laboratoire d'ImmunoRhumatologie Moléculaire, INSERM UMR_S1109, Plateforme GENOMAX, Faculté de Médecine, Fédération Hospitalo-Universitaire OMICARE, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France. .,Labex TRANSPLANTEX, Faculté de Médecine, Université de Strasbourg, Strasbourg, France. .,INSERM Franco-Japanese Nextgen HLA Laboratory, Strasbourg, France. .,INSERM Franco-Japanese Nextgen HLA Laboratory, Nagano, Japan. .,Laboratoire d'Immunologie, Plateau Technique de Biologie, Pôle de Biologie, Nouvel Hôpital Civil, Strasbourg, France.
| |
Collapse
|
7
|
Positive association between MIC gene polymorphism and tuberculosis in Chinese population. Immunol Lett 2019; 213:62-69. [PMID: 31400356 DOI: 10.1016/j.imlet.2019.07.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2019] [Revised: 07/29/2019] [Accepted: 07/30/2019] [Indexed: 11/23/2022]
Abstract
The disease progression and morbidity of tuberculosis (TB) infections are determined by virulence of the micro-organism, host genetic factors and environmental factors. The highly polymorphic MHC class I chain-related gene (MIC) could serve as a potential host genetic candidate. To investigate the association of MIC polymorphism with TB infection, 124 patients and 191 ethnically matched controls from Hunan province, Southern China, were genotyped for the MIC polymorphism using polymerase chain reaction-sequence specific priming and sequencing-based typing. The results showed that allele frequencies of MIC-sequence and MICA-STR were different in TB patients in comparison to normal controls (both P < 0.05). MICA-A4 and MICA*012:01 alleles were positive associated (OR = 2.42, 95% CI: 1.69-3.87; OR = 3.41, 95% CI: 2.19-5.33, respectively, both Pc < 0.05) while MICA -A5 were inversely associated (OR = 0.59, 95%CI: 0.41-0.94, Pc < 0.05) with TB. Homozygote MICA*012:01/012:01 was observed to have significant risk effects on TB (OR = 4.76, 95% CI: 1.94-11.69, Pc0000-0001-5151-1853 < 0.05). Additionally, MICB*008 allele conduct a significant risk effect for TB (OR = 3.17, 95%CI: 1.80-5.61, Pc < 0.05). All the data showed that MIC polymorphism was associated with the variable susceptibility to TB in Chinese population.
Collapse
|
8
|
Liu X, Chen X, Wei X, Meng Y, Liu L, Dai S. Genetic polymorphism analysis of MICB gene in Jing ethnic minority of Southern China. HLA 2018; 92:224-230. [PMID: 29934983 DOI: 10.1111/tan.13325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Revised: 06/08/2018] [Accepted: 06/17/2018] [Indexed: 12/01/2022]
Abstract
In the present study, the polymorphism in the 5'-upstream regulation region (5'-URR), coding region (exons 2-4), and the 3'-untranslated region (3'-UTR) of MICB gene were investigated for 150 healthy unrelated Jing individuals in Guangxi Zhuang Autonomous Region, by using PCR-SBT method. A total of 14 variation sites in the 5'-URR, 9 in coding region, and 6 in the 3'-UTR were detected in the Jing population. The MICB gene seems to present two different lineages showing functional variations mainly in nucleotides of the promoter region. Nineteen different MICB extended haplotypes (EHs) encompassing the 5'-URR, exons 2-4, and 3'-UTR were found in this population, and the most frequent was EH2 (20.33%). The findings here are of importance for future studies on the potential role of regulation region of MICB gene in disease association, transplantation, viral infection, and tumor progression among Jing population.
Collapse
Affiliation(s)
- Xuexiang Liu
- Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
| | - Xiang Chen
- Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
| | - Xiaomou Wei
- Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
| | - Yuming Meng
- Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
| | - Limin Liu
- Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
| | - Shengming Dai
- Medical Science Laboratory, The Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, Guangxi, 545005, China
| |
Collapse
|
9
|
Özlü F, Akçalı M, Yıldız ŞM, Yapıcıoğlu Yıldızdaş H, Gözet Y, Atay A. New biomarkers for antenatal infection: MICA and MICB gene expression in preterm babies. J Matern Fetal Neonatal Med 2017; 32:579-583. [DOI: 10.1080/14767058.2017.1387528] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
- Ferda Özlü
- Department of Neonatology, Faculty of Medicine, Çukurova University, Adana, Turkey
| | - Mustafa Akçalı
- Department of Neonatology, Faculty of Medicine, Çukurova University, Adana, Turkey
| | | | | | | | - Asena Atay
- Department of Neonatology, Faculty of Medicine, Çukurova University, Adana, Turkey
| |
Collapse
|
10
|
Wang W, Tian W, Zhu F, Li L, Cai J, Wang F, Liu K, Jin H, Wang J. MICA Gene Deletion in 3411 DNA Samples from Five Distinct Populations in Mainland China and Lack of Association with Nasopharyngeal Carcinoma (NPC) in a Southern Chinese Han population. Ann Hum Genet 2017; 80:319-326. [PMID: 27870115 DOI: 10.1111/ahg.12175] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2016] [Accepted: 09/23/2016] [Indexed: 12/20/2022]
Abstract
Deletion of major histocompatibility complex class I chain-related genes A (MICA*Del) was investigated in 3,411 DNA samples from two southern Chinese Han populations (Hunan Han, HNH; Guangdong Han, GDH), two northern Chinese populations (Inner Mongolia Han, IMH; Inner Mongolia Mongol, IMM) and one southeastern Chinese Han population (Fujian Han, FJH) using an in-house polymerase chain reaction-sequence specific priming (PCR-SSP) assay, which enables direct discrimination between heterozygote and homozygote for MICA*Del. MICA*Del showed a frequency ranging from 0.8% in FJH to 5.7% in IMM (Pcorrected < 0.05), indicating northward increase in frequency of MICA*Del in Chinese populations. In contrast to the association reported recently in a Taiwan Chinese population and a Malaysian Chinese cohort, MICA*Del distribution did not differ between 1,120 patients with nasopharyngeal carcinoma (NPC) and 1,483 normal controls in the HNH population (1.03% in NPC cases vs 1.18% in the controls, OR (95% CI) = 0.87 (0.51-1.47), p = 0.69). Further gender-stratified analysis also failed to disclose any male-specific association reported in a Taiwan Chinese population. Multi-locus typing of the 94 samples carrying MICA*Del revealed two new haplotypes, HLA-A*11:01-B*13:01-MICA*Del-MICB*009N-DRB1*04:06 and HLA-B*35:01-MICA*Del-MICB*009N-DRB1*15:01, in addition to HLA-B*48-MICA*Del. Unexpectedly, two samples with MICA*Del in the HNH population were each consistently found to have two distinct MICA alleles, indicating the existence of two MICA gene copies on certain HLA haplotypes. Based on the results from a sizeable case-control study, our data suggest that there is no association between MICA*Del and NPC in the southern Chinese Han population.
Collapse
Affiliation(s)
- WenYi Wang
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, Hunan, People's Republic of China
| | - Wei Tian
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, Hunan, People's Republic of China
| | - FaMing Zhu
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, People's Republic of China
| | - LiXin Li
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, Hunan, People's Republic of China
| | - JinHong Cai
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, Hunan, People's Republic of China
| | - Fan Wang
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, Hunan, People's Republic of China
| | - KangLong Liu
- Department of Nuclear Medicine, Hunan Cancer Hospital (the affiliated Cancer Hospital of XiangYa School of Medicine of Central South University), Changsha, Hunan, 410006, People's Republic of China
| | - HeKun Jin
- Department of Radiotherapy, Hunan Cancer Hospital (the affiliated Cancer Hospital of XiangYa School of Medicine of Central South University), Changsha, Hunan, 410006, People's Republic of China
| | - JunLong Wang
- Department of Laboratory Medicine, The 5th Hospital of Zhangzhou City, Zhangzhou, Fujian, People's Republic of China
| |
Collapse
|
11
|
Yildiz SM, Atli G, Gulec E, Guvenc B, Ozcengiz D. Major Histocompatibility Complex Class I-related Chain A and B Gene Expression in Sepsis Patient. INT J HUM GENET 2017. [DOI: 10.1080/09723757.2017.1305724] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- Sule Menziletoglu Yildiz
- Blood Bank, Cukurova University, Faculty of Medicine, Balcali Hospital, 01330, Saricam, Adana, Turkey
| | - Gulizar Atli
- Department of Biology, Cukurova University, Faculty of Science and Letters, 01330, Saricam Adana, Turkey
| | - Ersel Gulec
- Department of Anesthesiology, Cukurova University, Faculty of Medicine, Balcali Hospital, 01330, Saricam Adana, Turkey
| | - Birol Guvenc
- Blood Bank, Cukurova University, Faculty of Medicine, Balcali Hospital, 01330, Saricam, Adana, Turkey
- Hemapheresis, Stem Cell and Cryopreservation Unit, Cukurova University, Balcali Hospital, 01330, Saricam Adana, Turkey
- Division of Internal Medicine, Hematology Department, Cukurova University, Faculty of Medicine, Balcali Hospital, 01330, Saricam Adana, Turkey
| | - Dilek Ozcengiz
- Department of Anesthesiology, Cukurova University, Faculty of Medicine, Balcali Hospital, 01330, Saricam Adana, Turkey
| |
Collapse
|
12
|
Wang WY, Tian W, Wang F, Zhu FM, Wang PX, Xing LF. A new MICA allele, MICA*007:07, characterized by cloning and sequencing. Int J Immunogenet 2017; 44:145-147. [PMID: 28371368 DOI: 10.1111/iji.12311] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2016] [Revised: 01/16/2017] [Accepted: 02/20/2017] [Indexed: 11/30/2022]
Abstract
A new MICA allelic variant, MICA*007:07, was identified in an individual of Mongol ethnicity in the Inner Mongolia Autonomous Region, northern China. Following polymerase chain reaction-sequence-based typing (PCR-SBT), this new allele was further confirmed by cloning and sequencing. MICA*007:07 differs from MICA*007:01 by a synonymous mutation from G to A at the 2nd nucleotide position in exon 2. MICA*007:07 was linked to HLA-B*27:05.
Collapse
Affiliation(s)
- W Y Wang
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, China
| | - W Tian
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, China
| | - F Wang
- Immunogenetics Research Group, Department of Immunology, College of Basic Medical Sciences, Central South University, Changsha, China
| | - F M Zhu
- HLA Typing Laboratory, Blood Center of Zhejiang Province, Hangzhou, Zhejiang, China.,Key Laboratory of Blood Safety Research, Ministry of Health, Hangzhou, China
| | - P X Wang
- Inner Mongolia Medical University, Hohhot, China
| | - L F Xing
- Department of Neurology, Hospital of Inner Mongolia North Heavy Industry Group Company Limited, Baotou, China
| |
Collapse
|
13
|
Risti M, Bicalho MDG. MICA and NKG2D: Is There an Impact on Kidney Transplant Outcome? Front Immunol 2017; 8:179. [PMID: 28289413 PMCID: PMC5326783 DOI: 10.3389/fimmu.2017.00179] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2016] [Accepted: 02/07/2017] [Indexed: 01/06/2023] Open
Abstract
This paper aims to present an overview of MICA and natural killer group 2 member D (NKG2D) genetic and functional interactions and their impact on kidney transplant outcome. Organ transplantation has gone from what can accurately be called a “clinical experiment” to a routine and reliable practice, which has proven to be clinically relevant, life-saving and cost-effective when compared with non-transplantation management strategies of both chronic and acute end-stage organ failures. The kidney is the most frequently transplanted organ in the world (transplant-observatory1). The two treatment options for end-stage renal disease (ESRD) are dialysis and/or transplantation. Compared with dialysis, transplantation is associated with significant improvements in quality of life and overall longevity. A strong relationship exists between allograft loss and human leukocyte antigens (HLA) antibodies (Abs). HLA Abs are not the only factor involved in graft loss, as multiple studies have shown that non-HLA antigens are also involved, even when a patient has a good HLA matche and receives standard immunosuppressive therapy. A deeper understanding of other biomarkers is therefore important, as it is likely to lead to better monitoring (and consequent success) of organ transplants. The objective is to fill the void left by extensive reviews that do not often dive this deep into the importance of MICA and NKG2D in allograft acceptance and their partnership in the immune response. There are few papers that explore the relationship between these two protagonists when it comes to kidney transplantation. This is especially true for the role of NKG2D in kidney transplantation. These reasons give a special importance to this review, which aims to be a helpful tool in the hands of researchers in this field.
Collapse
Affiliation(s)
- Matilde Risti
- LIGH - Immunogenetics and Histocompatibility Laboratory, Federal University of Paraná , Curitiba , Brazil
| | - Maria da Graça Bicalho
- LIGH - Immunogenetics and Histocompatibility Laboratory, Federal University of Paraná , Curitiba , Brazil
| |
Collapse
|
14
|
MICB gene diversity and balancing selection on its promoter region in Yao population in southern China. Hum Immunol 2016; 77:1187-1193. [DOI: 10.1016/j.humimm.2016.08.015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2016] [Revised: 08/09/2016] [Accepted: 08/30/2016] [Indexed: 11/19/2022]
|
15
|
Nomenclature for factors of the HLA system, update April 2016. Hum Immunol 2016; 77:1300-1303. [PMID: 27702576 DOI: 10.1016/j.humimm.2016.09.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
16
|
Marsh SGE. Nomenclature for factors of the HLA system, update April 2016. HLA 2016; 88:131-5. [DOI: 10.1111/tan.12857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
17
|
Marsh SGE. Nomenclature for factors of the HLA system, update April 2016. Int J Immunogenet 2016; 43:310-3. [PMID: 27511605 DOI: 10.1111/iji.12286] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|